145 related articles for article (PubMed ID: 38362771)
1. Is there a prognostic difference among stage I lung adenocarcinoma patients with different BRAF-mutation status?
Ma SS; Wang RR; Peng Q; Liu Y; Qian JY; Li MJ; Li K; Huang ZY; Wu LL; Xie D
Thorac Cancer; 2024 Mar; 15(9):715-721. PubMed ID: 38362771
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
[TBL] [Abstract][Full Text] [Related]
5. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
[TBL] [Abstract][Full Text] [Related]
6. Detecting acquired V-Raf murine sarcoma viral oncogene homolog B1 V600E mutation associated with osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma: A case report.
Hagihara Y; Suetsugu T; Uto H; Kozono T; Masada Y; Satozono Y; Shinmura M; Koreeda Y; Mizuno K; Inoue H
Respir Investig; 2024 Jan; 62(1):13-15. PubMed ID: 37925883
[TBL] [Abstract][Full Text] [Related]
7. Distinct mutational features across preinvasive and invasive subtypes identified through comprehensive profiling of surgically resected lung adenocarcinoma.
Xiang C; Ji C; Cai Y; Teng H; Wang Y; Zhao R; Shang Z; Guo L; Chen S; Lizaso A; Lin J; Wang H; Li B; Zhang Z; Zhao J; Wei J; Liu J; Zhu L; Fang W; Han Y
Mod Pathol; 2022 Sep; 35(9):1181-1192. PubMed ID: 35641658
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma.
Zheng D; Wang R; Pan Y; Zheng S; Zhang Y; Li H; Cheng C; Gong R; Li Y; Shen X; Hu H; Cai D; Cheng X; Sun Y; Chen H
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1284-91. PubMed ID: 26202550
[TBL] [Abstract][Full Text] [Related]
9. Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid.
Frankel D; Nanni-Metellus I; Robaglia-Schlupp A; Tomasini P; Guinde J; Barlesi F; Astoul P; Ouafik L; Amatore F; Secq V; Kaspi E; Roll P
Clin Chem Lab Med; 2018 Apr; 56(5):851-856. PubMed ID: 29306909
[TBL] [Abstract][Full Text] [Related]
10. The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma.
Zhou W; Liu Z; Wang Y; Zhang Y; Qian F; Lu J; Wang H; Gu P; Hu M; Chen Y; Yang Z; Zhao R; Lou Y; Han B; Zhang W
Cancer Med; 2022 Mar; 11(5):1299-1309. PubMed ID: 35023616
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.
Isaka T; Ito H; Yokose T; Saito H; Adachi H; Murakami K; Miura J; Kikunishi N; Rino Y
BMC Cancer; 2022 Sep; 22(1):966. PubMed ID: 36085020
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.
Singh V; Guleria P; Malik PS; Mohan A; Thulkar S; Pandey RM; Luthra K; Arava S; Ray R; Jain D
Curr Probl Cancer; 2019 Oct; 43(5):391-401. PubMed ID: 30591192
[TBL] [Abstract][Full Text] [Related]
13. Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.
Ohba T; Toyokawa G; Osoegawa A; Hirai F; Yamaguchi M; Taguchi K; Seto T; Takenoyama M; Ichinose Y; Sugio K
Surg Today; 2016 Sep; 46(9):1091-8. PubMed ID: 26711128
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation.
Ding X; Zhang Z; Jiang T; Li X; Zhao C; Su B; Zhou C
Cancer Med; 2017 Mar; 6(3):555-562. PubMed ID: 28135039
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma.
Li Z; Jiang L; Bai H; Wang Z; Zhao J; Duan J; Yang X; An T; Wang J
Thorac Cancer; 2015 May; 6(3):269-74. PubMed ID: 26273372
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
Ma Z; Zhang Y; Deng C; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e73-e85. PubMed ID: 32739163
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma.
Shan L; Qiu T; Ling Y; Guo L; Zheng B; Wang B; Li W; Li L; Ying J
PLoS One; 2015; 10(6):e0130447. PubMed ID: 26102513
[TBL] [Abstract][Full Text] [Related]
18. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
[TBL] [Abstract][Full Text] [Related]
19. The radiological characteristics, tertiary lymphoid structures, and survival status associated with EGFR mutation in patients with subsolid nodules like stage I-II LUAD.
Xie M; Gao J; Ma X; Song J; Wu C; Zhou Y; Jiang T; Liang Y; Yang C; Bao X; Zhang X; Yao J; Jing Y; Wu J; Wang J; Xue X
BMC Cancer; 2024 Mar; 24(1):372. PubMed ID: 38528507
[TBL] [Abstract][Full Text] [Related]
20. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
